Vera Therapeutics (VERA) Income from Continuing Operations (2020 - 2026)
Vera Therapeutics (VERA) posted Income from Continuing Operations of 288249000.0 for Q1 2026, down 206.24% on a QoQ basis from 94125000.0 in Q4 2025, and down 365.36% year-over-year from 108625401.14 in Q1 2025.
Vera Therapeutics (VERA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Vera Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 288249000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 365.36% year-over-year to 288249000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 556310000.0 (down 165.96% YoY) and the FY2025 annual result came in at 62919000.0, up 6292000.0% from the prior year.
- Income from Continuing Operations was 288249000.0 for Q1 2026 at Vera Therapeutics, down from 94125000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 17651000.0 in Q1 2022 and bottomed at 288249000.0 in Q1 2026.
- A 5-year average of 60141882.35 and a median of 39053000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations rose 24.19% — and 2026, when it tumbled 365.36%.
- Vera Therapeutics' Income from Continuing Operations stood at 33189000.0 in 2022, then declined by 17.67% to 39053000.0 in 2023, then dropped by 28.21% to 50068000.0 in 2024, then sank by 87.99% to 94125000.0 in 2025, then slumped by 206.24% to 288249000.0 in 2026.
- Business Quant data shows VERA's Income from Continuing Operations at 288249000.0 in Q1 2026, 94125000.0 in Q4 2025, and 81420000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Vera Therapeutics | 2.55 Bn | 2.55 Bn | - | -288.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -288.25 Mn |
| Dec 31, 2025 | -94.13 Mn |
| Sep 30, 2025 | -81.42 Mn |
| Jun 30, 2025 | -92.52 Mn |
| Mar 31, 2025 | -61.94 Mn |
| Dec 31, 2024 | -50.07 Mn |
| Sep 30, 2024 | -53.00 Mn |
| Jun 30, 2024 | -44.16 Mn |
| Mar 31, 2024 | -33.50 Mn |
| Dec 31, 2023 | -39.05 Mn |
| Sep 30, 2023 | -25.26 Mn |
| Jun 30, 2023 | -21.01 Mn |
| Mar 31, 2023 | -30.51 Mn |
| Dec 31, 2022 | -33.19 Mn |
| Sep 30, 2022 | -33.32 Mn |
| Jun 30, 2022 | -23.44 Mn |
| Mar 31, 2022 | -17.65 Mn |
| Dec 31, 2021 | -16.60 Mn |
| Sep 30, 2021 | -7.25 Mn |
| Jun 30, 2021 | -5.85 Mn |